Aclaris Therapeutics, Inc.
ACRSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United. At a $892.0M market cap, Aclaris Therapeutics, Inc. ranks as a small-cap company within healthcare. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various di.
Market Cap
$892.0M
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-7.70
EPS (TTM)
$-0.58
EPS (Fwd)
$-0.79
ROE
-59.1%
ROA
-29.0%
Cash
$91.6M
Total Debt
$1.9M
Free CF
-$42.0M
52W Change
202.5%
Annual Financials
Cash vs Debt
Where ACRS stands vs its 150-day and 200-day moving averages
As of the September 1, 2026 close, ACRS finished 33.55% above its 150-day moving average ($4.53) and 46.14% above its 200-day moving average ($4.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACRS overbought or oversold?
At the September 1, 2026 close, ACRS's RSI(14) was 53.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $91.6M in cash and $1.9M in debt, ACRS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$42.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -59.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $29.8M (2022) to $7.8M (2025), a 74% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aclaris Therapeutics, Inc.'s trajectory.